How to Get Belsomra (Suvorexant) in Maine

What Is Suvorexant and Why Is It Prescribed?

Suvorexant is a dual orexin receptor antagonist (DORA) that blocks wakefulness-promoting orexin-A and orexin-B neuropeptides in the lateral hypothalamus. The FDA approved Belsomra in August 2014 for adults with insomnia characterized by difficulty falling asleep, staying asleep, or both. Unlike benzodiazepines and Z-drugs that amplify GABAergic inhibition, suvorexant works by suppressing the arousal signal itself.

In the key phase III trial by Herring et al. (2014, Lancet Neurology, N=3,110), suvorexant at doses of 40 mg and 20 mg significantly improved both subjective total sleep time (sTST) and subjective time to sleep onset (sTSO) versus placebo over four weeks. The 20 mg dose increased sTST by approximately 22 minutes and reduced sTSO by roughly 8 minutes compared to placebo. The most frequently reported adverse event was somnolence, occurring in 7% of suvorexant patients versus 3% on placebo [1].

The FDA-approved prescribing information recommends starting at 10 mg taken no more than once per night, within 30 minutes of bedtime, with at least 7 hours remaining before planned awakening [2]. The maximum approved dose is 20 mg. This distinction matters in Maine because prescribers sometimes begin at 5 mg in older adults or patients taking moderate CYP3A inhibitors, then titrate based on clinical response.

Who Can Prescribe Belsomra in Maine?

Any clinician holding an active Maine prescriptive authority license and a valid DEA registration for Schedule IV substances can prescribe suvorexant. That includes MDs, DOs, nurse practitioners (APRNs), and physician assistants (PAs).

Maine statute (32 MRSA §2102) grants APRNs independent prescriptive authority without a collaborative agreement, a policy in effect since 1995. This makes Maine one of the most accessible states for patients seeking a Belsomra prescription from a nurse practitioner without requiring a supervising physician's sign-off. PAs in Maine prescribe under a practice agreement with a physician, but Schedule IV drugs like suvorexant fall well within standard PA scope [3].

The practical takeaway: you do not need to see a sleep specialist. A primary care provider, psychiatrist, or any qualified prescriber can evaluate your insomnia and write for suvorexant after confirming the diagnosis and ruling out contraindications. The American Academy of Sleep Medicine (AASM) clinical practice guideline lists orexin receptor antagonists as a recommended pharmacotherapy option for sleep-maintenance insomnia in adults [4].

Telehealth Access to Belsomra in Maine

Maine permits telehealth prescribing of Schedule IV controlled substances. Yes, that includes suvorexant. The state adopted permanent telehealth parity legislation (LD 1075, signed 2021) requiring private insurers to cover telehealth services at the same rate as in-person visits. MaineCare also reimburses telehealth encounters for behavioral health and medication management.

A telehealth visit for insomnia typically follows this workflow:

1. Intake and screening. The provider reviews your sleep history, screens for obstructive sleep apnea (OSA) using the STOP-Bang questionnaire, and checks for comorbid psychiatric conditions.
2. Medication reconciliation. Suvorexant is contraindicated with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) and in patients with narcolepsy. The provider confirms none of these apply.
3. Prescription issuance. The prescriber sends an electronic prescription (EPCS) directly to a Maine pharmacy. Maine mandates e-prescribing for controlled substances under 22 MRSA §7253.
4. Follow-up. Most providers schedule a 2-to-4-week check-in to assess efficacy and side effects before continuing or adjusting the dose.

The DEA's telemedicine prescribing rule requires that patients have at least one qualifying interaction with the prescriber before receiving a controlled substance via telehealth, though temporary flexibilities introduced during the COVID-19 public health emergency have been extended through federal rulemaking. Maine-licensed telehealth platforms can prescribe suvorexant to patients physically located in Maine at the time of the encounter.

Maine Medicaid (MaineCare) and Insurance Coverage

MaineCare, Maine's Medicaid program, covers Belsomra with prior authorization (PA). The PA requirement reflects suvorexant's position as a branded, higher-cost sleep agent relative to generic alternatives like zolpidem or trazodone.

A typical PA request for Belsomra under MaineCare requires:

• Documentation that the patient has tried and failed (or has a documented intolerance to) at least one preferred generic sleep agent
• A clinical diagnosis of insomnia disorder per DSM-5 criteria (780.52 / ICD-10 G47.00)
• Prescriber attestation that cognitive behavioral therapy for insomnia (CBT-I) was offered or considered
• Confirmation that the patient does not have narcolepsy or severe hepatic impairment

The AASM practice parameters recommend CBT-I as first-line treatment for chronic insomnia, with pharmacotherapy as an adjunct or alternative when CBT-I is unavailable, ineffective, or not tolerated [4]. Many insurers, including MaineCare, reference this guideline in their PA criteria.

For commercial plans in Maine (Anthem, Aetna, Cigna, Harvard Pilgrim), coverage varies by formulary tier. Belsomra often sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $40 to $75 for a 30-day supply. A manufacturer savings card from Merck may reduce out-of-pocket costs for commercially insured patients, though these cards do not apply to government-funded insurance.

The retail cash price for 30 tablets of Belsomra 10 mg averages $380 to $420 nationally. Generic suvorexant became available in late 2023 after patent expiration, and generic pricing can drop the 30-day cost to $30 to $80 depending on the pharmacy, making PA less of a barrier than it was when only the brand existed.

Filling Your Prescription: Retail and 503A Pharmacies in Maine

Once your prescriber transmits the e-prescription, you can fill suvorexant at any licensed retail pharmacy in Maine. CVS, Walgreens, Walmart, Hannaford, and independent pharmacies throughout Portland, Bangor, Lewiston, and smaller communities all stock Belsomra or its generic equivalent.

For patients requesting compounded formulations, Maine licenses 503A compounding pharmacies under the Maine Board of Pharmacy (10-144 CMR Chapter 21). A 503A pharmacy can compound suvorexant into alternative dosage forms (sublingual troches, flavored suspensions) if a prescriber determines that a commercially available form does not meet the patient's clinical needs. This route requires a patient-specific prescription. The compound can be shipped within Maine's borders.

Filling timelines in Maine break down as follows:

• No PA required (commercial plan or cash pay). Same day to 1 business day at most retail pharmacies.
• PA required (MaineCare or restrictive commercial plan). 2 to 5 business days. Your prescriber's office submits the PA electronically; Maine's Medicaid fiscal agent (currently Gainwell Technologies) adjudicates most PA requests within 24 to 72 hours.
• 503A compounded order. 3 to 7 business days for preparation and dispensing, plus shipping time if not picked up locally.

What Labs and Evaluations Are Needed Before Starting Belsomra?

No routine blood work is required before prescribing suvorexant. The FDA label does not mandate baseline laboratory testing [2]. This contrasts with drugs like lemborexant, where hepatic function receives additional labeling attention, or with ramelteon, where liver enzymes are sometimes checked.

However, a clinical evaluation should include:

Sleep apnea screening. Suvorexant does not treat and may theoretically worsen obstructive sleep apnea. The prescriber should use a validated screening tool (STOP-Bang, Epworth Sleepiness Scale) and refer for polysomnography if moderate-to-severe OSA is suspected. A study published in Chest (2016) found that suvorexant did not significantly worsen the apnea-hypopnea index in patients with mild-to-moderate OSA (N=26), but the sample was small and the findings should not replace formal screening [5].

Depression and suicidality assessment. Insomnia is both a symptom and a risk factor for major depressive disorder. The FDA label includes a warning about worsening depression and suicidal ideation. A brief screening instrument (PHQ-9) is standard of care.

Medication interaction review. Suvorexant is metabolized primarily by CYP3A4. The dose must be reduced to 5 mg when co-administered with moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, verapamil). Strong CYP3A4 inhibitors are an absolute contraindication [2]. The prescriber should also check for concomitant CNS depressants (opioids, benzodiazepines, alcohol) that could potentiate sedation.

Hepatic function consideration. While no labs are required, suvorexant exposure increases in patients with moderate hepatic impairment (Child-Pugh B), and the drug has not been studied in severe hepatic impairment (Child-Pugh C). The prescriber should document known liver disease status.

Transferring a Belsomra Prescription to Maine

If you hold a valid suvorexant prescription from an out-of-state provider, Maine pharmacies can accept a transferred Schedule IV prescription under DEA regulations (21 CFR §1306.25). The transfer must occur directly between pharmacies (pharmacist-to-pharmacist communication or through a shared real-time database). Each Schedule IV prescription may be transferred up to the number of remaining authorized refills.

For patients relocating to Maine, the more practical route is establishing care with a Maine-licensed provider who can issue a new prescription. Telehealth makes this efficient. Bring your medication history, including the dose and pharmacy records, to expedite the visit.

Maine does not impose additional state-level restrictions on controlled substance prescription transfers beyond the federal framework. The Maine Board of Pharmacy rules defer to DEA transfer protocols for Schedule III through V drugs.

Suvorexant Dosing, Safety, and Clinical Pearls for Maine Patients

The recommended starting dose is 10 mg once nightly, 30 minutes before bed. If 10 mg is well tolerated but insufficiently effective after at least one week, the dose may be increased to 20 mg. The 5 mg dose is reserved for patients on moderate CYP3A4 inhibitors or those who experience excessive next-day somnolence at 10 mg [2].

Three safety points deserve specific attention:

Next-morning impairment. The FDA required Merck to study next-day driving performance. In a randomized crossover trial, suvorexant 20 mg impaired driving performance (measured by standard deviation of lateral position, SDLP) in some subjects 9 hours post-dose, particularly in women and at higher doses. Patients should be advised to allow a full 7 hours of sleep opportunity and to assess their own alertness before driving.

Sleep paralysis and hypnagogic hallucinations. As a class effect of orexin antagonism, approximately 1% of clinical trial subjects reported sleep paralysis, and <1% reported hallucinations [1]. These events were transient and resolved with dose reduction or discontinuation.

No physical dependence signal. In the Herring et al. phase III data, abrupt discontinuation of suvorexant after 12 months of use did not produce rebound insomnia beyond one night, and withdrawal symptoms were not statistically different from placebo [1]. This compares favorably with Z-drugs and benzodiazepines, which carry well-documented dependence risk. The American Geriatrics Society Beers Criteria (2023) lists benzodiazepine receptor agonists as potentially inappropriate in older adults but does not include DORAs in the same category [6].

How Suvorexant Compares to Other Insomnia Drugs Available in Maine

Maine patients have access to several insomnia pharmacotherapies. A brief comparison helps contextualize where suvorexant fits:

Suvorexant vs. zolpidem (Ambien). Zolpidem is a GABA-A receptor agonist, generic, and inexpensive ($5 to $15/month). It carries higher risk of complex sleep behaviors (sleepwalking, sleep-driving) and rebound insomnia on discontinuation. Suvorexant has a lower complex-sleep-behavior incidence in trial data but costs significantly more at brand pricing [2].

Suvorexant vs. lemborexant (Dayvigo). Lemborexant is another DORA, approved in 2019. The SUNRISE-2 trial (N=949) demonstrated sustained efficacy over 12 months at 5 mg and 10 mg doses (Rosenberg et al., 2019, JAMA Network Open) [7]. Head-to-head data between suvorexant and lemborexant are limited, but both share the DORA mechanism. Lemborexant is also Schedule IV and requires PA under MaineCare.

Suvorexant vs. CBT-I. Cognitive behavioral therapy for insomnia remains the guideline-recommended first-line treatment. A meta-analysis published in Annals of Internal Medicine (2015) found that CBT-I produced durable improvements in sleep-onset latency (mean reduction of 19 minutes) and wake after sleep onset that persisted beyond the treatment period, unlike pharmacotherapy effects that typically end upon discontinuation [8]. In practice, the two approaches are often combined.

Prior Authorization Step-by-Step for Maine Prescribers

For clinicians navigating MaineCare PA for suvorexant, the process follows the state's standard pharmacy PA workflow:

1. Prescribe suvorexant electronically. The pharmacy submits the claim to MaineCare.
2. If the claim rejects with a PA-required code, the pharmacy notifies your office.
3. Complete the PA request form through the Maine Medicaid portal or via fax to the PA vendor. Include: diagnosis code (G47.00), prior medication trials with dates and outcomes, clinical rationale for suvorexant over formulary alternatives.
4. The PA review targets a 24-hour turnaround for standard requests and 24 hours for urgent requests.
5. If approved, the authorization typically lasts 12 months and covers up to a 30-day supply per fill.
6. If denied, you can file a formal appeal. The appeal is reviewed by a clinical pharmacist or physician reviewer independent of the initial decision.

The single most common denial reason is insufficient documentation of prior formulary agent trial. Include specific drug names, doses, durations, and the reason for discontinuation (lack of efficacy, adverse effect, or both).